key: cord-0431214-4k9td25i
authors: Uschner, D.; Bott, M.; Santacatterina, M.; Gunaratne, M. P.; Fette, L.; Burke, B. K.; Strylewicz, G.; Edelstein, S. L.; Lagarde, W. H.; Miller, K. E.; Weintraub, W. S.; Yukich, J.; Tapp, H.; Schieffelin, J.; Ahmed, A.; Berry, A. A.; Munawar, I.; Seals, A. L.; Williamson, J.; Herrington, D.; Sanders, J. W.; Runyon, M.; Partnership, COVID-19 Community Research
title: Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina
date: 2021-10-13
journal: nan
DOI: 10.1101/2021.10.10.21264812
sha: 3b77a74f348f32299200ee35bceff4ff2c515449
doc_id: 431214
cord_uid: 4k9td25i

Importance: Real-world data are needed to assess incidence and factors associated with breakthrough SARS-CoV-2 infections following vaccination. Objective: Estimate incidence of breakthrough infections and assess associations with risk factors using self-reported data from a large NC population sample. Design: Prospective observational cohort study utilizing daily online survey data to capture information about COVID-19 symptoms, testing, and vaccination status. Setting: Six health care systems in North Carolina with data collected between January 15, 2021 and September 24, 2021. Participants: Adult study participants who reported full vaccination with a COVID-19 mRNA or J&J non-replicating viral vector vaccine (n = 16,020). Exposures: Potential community exposure to SARS-CoV-2. Main Outcome and Measures: Self-reported breakthrough infection. Results: SARS-CoV-2 infection after vaccination was self-reported in 1.9% of participants, with an incidence rate of 7.3 per 100,000 person-years. Younger age (45-64 vs. 18-44: HR (95% CI) = 0.65 (0.51-0.82); 65+ vs. 18-44: HR (95% CI) = 0.59 (0.39-0.90)), and vaccination with J&J Ad26.COV2.S were associated with a higher risk of breakthrough infection compared to vaccination with Pfizer BNT162b2 (Ad26.COV2.S vs. BNT162b2: HR (95% CI) = 2.23 (1.40-3.56)), while participants vaccinated with mRNA-1273 (mRNA-1273 vs. BNT162b2: HR (95% CI) = 0.69 (0.50-0.96) and those residing in urban counties experienced a lower rate of SARS-CoV-2 breakthrough infection compared with those from suburban (HR (95% CI) = 1.39 (1.01-1.90)) or rural (HR (95% CI) = 1.57 (1.16-2.11)) counties. There was no significant association between breakthrough infection and participant sex, race, healthcare worker status, prior COVID-19 infection, routine mask use, or overall vaccination rate in the county of residence. Conclusions and Relevance: This NC community-based observational study showed that the proportion of the cohort who self-report breakthrough SARS-CoV-2 infections was 7.3 events per 100,000 person-years. Younger adults, those vaccinated with J&J Ad26.COV2.S, and those residing in suburban or rural counties were at higher risk of breakthrough infections and should be targeted for additional risk mitigation strategies to decrease community transmission.

Introduction Despite the remarkable clinical trial efficacy 1-3 and real-world effectiveness of the SARS-CoV-2 vaccines, 4 breakthrough infections do occur, potentially with significant clinical and public health consequences. [5] [6] [7] While vaccine effectiveness appears to wane over time, 8, 9 studies of breakthrough infection have focused largely on subsequent healthcare utilization and clinical outcomes. 10, 11 Little is known about the risk factors associated with breakthrough infection such as age, race, sex, community exposure and behavior, and history of prior COVID- 

The NC CRP is a prospective, observational cohort study that solicited participants for COVID-19 symptoms, test results, vaccination status and risk behavior via daily email or text surveys.

Adults 18 years and older were enrolled between April 13, 2020 and August 14, 2021 at six NC healthcare systems (http://www.covid19communitystudy.org/). This study was approved by the Wake Forest School of Medicine Institutional Review Board. Participants consented to allow access to their electronic health records (EHR). Demographic data and healthcare worker status were collected at enrollment. Counties of residence were classified as urban, suburban or rural based on population density estimates. 12 Symptoms of COVID-19 included fever, chills, cough, shortness of breath, fatigue, muscle pain, headache, loss of taste/smell, sore throat, congestion/runny nose, nausea/vomiting, and diarrhea. We defined SARS-CoV-2 vaccination as participant self-report of receiving two doses of either the Pfizer BioNTech BNT162b2 or . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 13, 2021. were estimated as number of events by person time. Cox proportional hazards models were used to estimate unadjusted and adjusted hazard ratios with 95% confidence intervals (CI). Only main effects were considered in the analysis. Three participants who did not specify their sex at enrollment were excluded from analysis. There were no other missing data. All variables of interest were selected a-priori and were used as covariates in the multivariable model. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 13, 2021. weeks among uninfected participants. The cumulative incidence of breakthrough infection was 5.2% at 34 weeks following full vaccination (Figure 1 ). In the multivariable analysis (Table 1) 

In this community-based observational study, the cumulative incidence of participants in North Carolina who self-reported SARS-CoV-2 infection was 5.2% by 34 weeks following full vaccination. The study period included a statewide surge in cases driven by the Delta variant, with a comparable number of new cases as during the winter of 2020-21. The overall breakthrough infection event rate was 7.3 events per 100,000 person-years. Participants . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 13, 2021. ; https://doi.org/10.1101/2021.10.10.21264812 doi: medRxiv preprint vaccinated with Ad26.COV2.S, participants younger than 45 years, and those from rural and suburban counties were at higher risk of breakthrough infection. The association with younger age may reflect more frequent exposures, higher risk exposures, age-associated differences in mitigation behaviors, or a combination of these factors. The association with rural residence may reflect increased transmission in areas with generally lower rates of vaccination 13-15 though we did not find a significant difference in breakthrough infection rates when comparing counties with a high (≥ 60%) vs low (< 60%) overall vaccination rate. Race/ethnicity, sex, and occupation as healthcare workers were not associated with higher risk for infection after vaccination. The analysis did not detect a difference in breakthrough infection rates based on general mask usage as a proxy for COVID-19 risk mitigation behavior. However, the conclusions from general mask usage is limited because it is not linked to a specific exposure.

These findings may be limited by selection and reporting biases and may not be generalizable to other areas of the country. Participants were largely recruited through their affiliated healthcare system or EHR (e.g. through electronic patient portal systems); therefore, they may be more engaged in healthcare than the general population. This study includes self-report of a new positive test for COVID-19, generally accompanied by symptoms, so paucisymptomatic or asymptomatic infections may be missed. The results are dependent on transmission rates within the community, which will vary during the course of the pandemic.

In conclusion, this large NC based observational study conducted in a real-world setting demonstrated an event rate of 7.3 breakthrough infections per 100,000 person-years.

Breakthrough infection occurred at a higher rate in rural parts of North Carolina, among the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 13, 2021. ; https://doi.org/10.1101/2021.10.10.21264812 doi: medRxiv preprint younger population and those vaccinated with Ad26.COV2.S. While the underlying causes of the observed differences in breakthrough infection rates deserve further study, our findings suggest that younger adults, those who received the Ad26.COV2.S vaccination, and those residing in suburban and rural counties should be targeted for additional risk mitigation strategies to prevent infection and further transmission of SARS-CoV-2.

The COVID-19 Community Research Partnership gratefully acknowledges the commitment and dedication of the study participants. Programmatic, laboratory, and technical support was provided by Vysnova Partners, Inc., Javara, Inc., and Oracle Corporation. 

The CARES Act of the U.S. of the HHS had no role.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 13, 2021. ; https://doi.org/10.1101/2021.10.10.21264812 doi: medRxiv preprint

Dr. Uschner and Mr. Bott had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 13, 2021. ; https://doi.org/10.1101/2021.10.10.21264812 doi: medRxiv preprint

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Safety and Efficacy of the BNT162b2 mRNA Covid

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

Real World SARS-CoV2 Vaccine Effectiveness: The North Carolina COVID-19 Community Research Partnership

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination

Rural North Carolina hospital leader emerges as outspoken critic of COVID 'noise'. 2021

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 13, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 13, 2021. ; https://doi.org/10.1101/2021.10.10.21264812 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 13, 2021. ; https://doi.org/10.1101/2021.10.10.21264812 doi: medRxiv preprint